Regeneron And Sanofi Receive Complete Response Letter From FDA; Refers To Certain Deficiencies In Mfg Practice At Sanofi Facility; Satisfactory Resolution Of These Deficiencies Is Required Before The FDA Will Grant Approval For Sarilumab